ATE278391T1 - Verfahren zur herstellung kristalliner partikel - Google Patents

Verfahren zur herstellung kristalliner partikel

Info

Publication number
ATE278391T1
ATE278391T1 AT99963730T AT99963730T ATE278391T1 AT E278391 T1 ATE278391 T1 AT E278391T1 AT 99963730 T AT99963730 T AT 99963730T AT 99963730 T AT99963730 T AT 99963730T AT E278391 T1 ATE278391 T1 AT E278391T1
Authority
AT
Austria
Prior art keywords
solvent
crystalline particles
substance
treatment
water
Prior art date
Application number
AT99963730T
Other languages
English (en)
Inventor
Mikael Bisrat
Saeed Moshashee
Hakan Nyqvist
Mustafa Demirbueker
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20413378&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE278391(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE278391T1 publication Critical patent/ATE278391T1/de

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D11/00Solvent extraction
    • B01D11/04Solvent extraction of solutions which are liquid
    • B01D11/0403Solvent extraction of solutions which are liquid with a supercritical fluid
    • B01D11/0411Solvent extraction of solutions which are liquid with a supercritical fluid the supercritical fluid acting as solvent for the solvent and as anti-solvent for the solute, e.g. formation of particles from solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4458Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1688Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AT99963730T 1998-11-23 1999-11-22 Verfahren zur herstellung kristalliner partikel ATE278391T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9804001A SE9804001D0 (sv) 1998-11-23 1998-11-23 New process
PCT/SE1999/002153 WO2000030613A1 (en) 1998-11-23 1999-11-22 New process

Publications (1)

Publication Number Publication Date
ATE278391T1 true ATE278391T1 (de) 2004-10-15

Family

ID=20413378

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99963730T ATE278391T1 (de) 1998-11-23 1999-11-22 Verfahren zur herstellung kristalliner partikel

Country Status (12)

Country Link
US (1) US6461642B1 (de)
EP (1) EP1133284B2 (de)
JP (1) JP4616993B2 (de)
AT (1) ATE278391T1 (de)
AU (1) AU767767B2 (de)
CA (1) CA2348084C (de)
DE (1) DE69920946T3 (de)
DK (1) DK1133284T4 (de)
ES (1) ES2228149T5 (de)
PT (1) PT1133284E (de)
SE (1) SE9804001D0 (de)
WO (1) WO2000030613A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH694686A5 (it) 2000-03-04 2005-06-15 Eco2 Sa Prodotto di micronizzazione di sostanze farmaceutiche.
GB0016040D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
ES2170008B1 (es) * 2000-08-25 2003-05-01 Soc Es Carburos Metalicos Sa Procedimiento para la precipitacion de particulas solidas finamente divididas.
FR2815540B1 (fr) * 2000-10-19 2005-06-10 Separex Sa Procede de fabrication de tres fines particules constituees d'un principe insere dans une molecule hote
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
GB0102075D0 (en) * 2001-01-26 2001-03-14 Astrazeneca Ab Process
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
CA2461349C (en) 2001-09-26 2011-11-29 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
RS29104A (en) * 2001-10-10 2006-12-15 Boehringer Ingelheim Pharmaceuticals Inc. Powder processing with pressurized gaseous fluids
FR2830760B1 (fr) * 2001-10-12 2004-06-04 Pf Medicament Procede de preparation d'un compose d'interaction de substances actives avec un support poreux par fluide supercritique
EP1572156A1 (de) * 2002-12-19 2005-09-14 Baxter International Inc. Verfahren zurherstellung von pharmazeutischen kombiformulierungen unter verwendung vonüberkritischen flüssigkeiten
KR20060015587A (ko) 2003-05-08 2006-02-17 넥타 쎄라퓨틱스 유케이 리미티드 미립물
EP1654001A2 (de) * 2003-08-05 2006-05-10 Boehringer Ingelheim International GmbH Medikamente zur inhalation mit steroiden und einem betamimetikum
ES2314465T5 (es) * 2003-11-19 2012-10-29 Natex Prozesstechnologie Gesmbh Un procedimiento y proceso para controlar los perfiles de temperatura, presión y densidad en procesos con fluidos densos y aparato asociado
EP1904219A4 (de) 2005-07-15 2011-07-27 Map Pharmaceuticals Inc Teilchenbildungsverfahren
EP1782839A1 (de) 2005-11-03 2007-05-09 Genetic S.p.A. Verfahren zur Sterilisation von Glucocorticosteroiden mit überkritischem CO2
JP2010500356A (ja) * 2006-08-09 2010-01-07 グラクソ グループ リミテッド ラクトースの製造方法
JP5825757B2 (ja) 2007-02-11 2015-12-02 マップ・ファーマシューティカルズ・インコーポレイテッド 副作用プロファイルを最小限にしながら片頭痛の迅速な緩和を可能にするdheの治療上の投与方法
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
WO2009047935A1 (ja) * 2007-10-12 2009-04-16 Ono Pharmaceutical Co., Ltd. 微粒子
JP5307382B2 (ja) * 2007-11-14 2013-10-02 日機装株式会社 微粒子化方法
PL2229233T3 (pl) * 2007-12-07 2020-03-31 Xspray Pharma Ab (Publ) Sposób wytwarzania cząstek
DE102008053618A1 (de) * 2008-10-29 2010-07-01 Karlsruher Institut für Technologie Verfahren zur Ausfällung von Salzen
ES2342140B1 (es) * 2008-12-30 2011-05-17 Consejo Superior Investigacion Procedimiento para la obtencion de micro- o nanoparticulas solidas
US20100294986A1 (en) * 2009-05-19 2010-11-25 Massachusetts Institute Of Technology Supercritical fluid facilitated particle formation in microfluidic systems
US20100298602A1 (en) * 2009-05-19 2010-11-25 Massachusetts Institute Of Technology Systems and methods for microfluidic crystallization
CA2767773C (en) 2011-02-11 2015-11-24 Grain Processing Corporation Composition comprising a salt and a crystallization interrupter
CN102327186A (zh) * 2011-09-30 2012-01-25 四川大学 一种采用超临界co2流体技术制备水溶性药物缓释微粒的方法
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3744329A1 (de) * 1987-12-28 1989-07-06 Schwarz Pharma Gmbh Verfahren zur herstellung einer mindestens einen wirkstoff und einen traeger umfassenden zubereitung
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US6063910A (en) 1991-11-14 2000-05-16 The Trustees Of Princeton University Preparation of protein microparticles by supercritical fluid precipitation
US5639441A (en) * 1992-03-06 1997-06-17 Board Of Regents Of University Of Colorado Methods for fine particle formation
US5301664A (en) * 1992-03-06 1994-04-12 Sievers Robert E Methods and apparatus for drug delivery using supercritical solutions
WO1994008599A1 (en) * 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Ion-pairing of drugs for improved efficacy and delivery
GB9313650D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9313642D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
SE9501384D0 (sv) * 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
US6126919A (en) * 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
GB9703673D0 (en) 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
WO1998041193A1 (en) 1997-03-20 1998-09-24 Schering Corporation Preparation of powder agglomerates

Also Published As

Publication number Publication date
DK1133284T4 (da) 2008-11-10
DE69920946D1 (de) 2004-11-11
ES2228149T3 (es) 2005-04-01
DE69920946T3 (de) 2009-02-26
CA2348084C (en) 2009-01-06
JP4616993B2 (ja) 2011-01-19
EP1133284B2 (de) 2008-08-06
AU2010300A (en) 2000-06-13
DK1133284T3 (da) 2005-02-28
US6461642B1 (en) 2002-10-08
CA2348084A1 (en) 2000-06-02
PT1133284E (pt) 2005-01-31
EP1133284A1 (de) 2001-09-19
ES2228149T5 (es) 2008-12-16
DE69920946T2 (de) 2005-08-25
SE9804001D0 (sv) 1998-11-23
EP1133284B1 (de) 2004-10-06
JP2002530318A (ja) 2002-09-17
AU767767B2 (en) 2003-11-20
WO2000030613A1 (en) 2000-06-02

Similar Documents

Publication Publication Date Title
ATE278391T1 (de) Verfahren zur herstellung kristalliner partikel
EE200100275A (et) Kristalsesse olekusse konverteeritud amorfse ja/või metastabiilse kristalse piirkonnaga osakeste valmistamismeetod
DE69124357D1 (de) Protein Nanomatrizen und Verfahren zur Herstellung
ATE168556T1 (de) Stabile budesonid-lösungen, verfahren zu deren herstellung sowie verwendung dieser lösungen als klistierzubereitungen und pharmazeutische schäume
ATE430368T1 (de) Verfahren und vorrichtung zur erzeugung von 18f- fluorid
ATE198982T1 (de) Verfahren zur herstellung von festen pharmazeutischen dosierungsformen hydrophobischen substanzen
NO20055817L (no) Apparat og fremgangsmate for behandling av injeksjonsfluid.
DE59500808D1 (de) Verfahren zur herstellung von partikeln bzw. pulvern
IS2667B (is) Lyfjablanda sem inniheldur andrógen
DE60028209D1 (de) Verfahren und apparat zur herstellung von extrakten und ölen aus pflanzen und anderen stoffen
FI972093A0 (fi) Jäteveden käsittelymenetelmä ja -laitos
ATE200024T1 (de) Verfahren zur herstellung von medizinischem kaugummi mit einem guten geschmack, enthaltend eine einschlussverbindung
ATE334682T1 (de) Verfahren zur herstellung von den trans-4-n- butylcyclohexanoicsaüre- und undecanoicsaüreestern von (7-alpha,11-beta)- dimethyl-17 beta -hydroxy-4-estren-3-one und deren medizynische anwendung
DE69839622D1 (de) Verfahren zur Herstellung eines künstlichen Organs, Hohlfasermembran, und Hohlfaserdialysator
JPS619857B2 (de)
DE59503394D1 (de) Verfahren zur Herstellung von Liposomen bzw. Proliposomen
FI971202A0 (fi) Levobupivakaiinin ja sen analogien valmistuksessa käytettäviä menetelmiä rasemisoinnin ja asymmetrisen muuntamisen tekemiseksi
DE60105528D1 (de) Verfahren zur Herstellung von porösen Polyimid durch Extraktion von Substanzen niedrigen Molekulargewichts mittels superkritischem Kohlendioxid
DE69021405T2 (de) System zur gesteuerten Freisetzung von Wirkstoffen sowie Verfahren zu dessen Herstellung.
DE50209881D1 (de) Herstellung von dialysekonzentrat aus einer hochverdichteten konzentratvorstufe und vorrichtung zur anwendung am dialyseplatz.
ES2155746B1 (es) Procedimiento y aparato para la produccion de carbon activo.
EP0537429B1 (de) Modifizierte Huminate, Verfahren zu ihrer Herstellung und Verwendung
ATE181826T1 (de) Wässriges liposomensystem sowie verfahren zur herstellung eines derartigen liposomensystems
HUP0103356A2 (hu) Eljárás és berendezés kénsavgőz eltávolítására
ATE222887T1 (de) Verfahren zur herstellung von inorganischen salzen von optisch aktiven phenylglycin-derivaten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1133284

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 1133284

Country of ref document: EP